At the time of writing, Oncology Institute Inc [TOI] stock is trading at $3.06, up 2.34%. An important factor to consider is whether the stock is rising or falling in short-term value. The TOI shares have gain 20.00% over the last week, with a monthly amount glided 41.67%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Oncology Institute Inc [NASDAQ: TOI] stock has seen the most recent analyst activity on May 15, 2025, when BTIG Research initiated its Buy rating and assigned the stock a price target of $7. On September 14, 2022, Guggenheim initiated with a Buy rating and assigned a price target of $7 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $10 on August 15, 2022.
For the past year, the stock price of Oncology Institute Inc fluctuated between $0.13 and $3.50. Currently, Wall Street analysts expect the stock to reach $8 within the next 12 months. Oncology Institute Inc [NASDAQ: TOI] shares were valued at $3.06 at the most recent close of the market. An investor can expect a potential return of 161.44% based on the average TOI price forecast.
Analyzing the TOI fundamentals
According to Oncology Institute Inc [NASDAQ:TOI], the company’s sales were 403.15M for trailing twelve months, which represents an 10.29% jump. Gross Profit Margin for this corporation currently stands at 0.1% with Operating Profit Margin at -0.13%, Pretax Profit Margin comes in at -0.16%, and Net Profit Margin reading is -0.17%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -5.1 and Total Capital is -0.5. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of5.61.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Oncology Institute Inc [NASDAQ:TOI] has a current ratio of 1.79. On the other hand, the Quick Ratio is 1.59, and the Cash Ratio is 0.67. Considering the valuation of this stock, the price to sales ratio is 0.68, the price to book ratio is 53.68.
Transactions by insiders
Recent insider trading involved Virnich Daniel, Chief Executive Officer, that happened on Mar 26 ’25 when 22640.0 shares were purchased. Chief Medical Officer, Podnos Yale completed a deal on Mar 26 ’25 to buy 9056.0 shares. Meanwhile, Director Pacala Mark L bought 90562.0 shares on Mar 26 ’25.
